BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 27798955)

  • 1. Inhibition of SRC family kinases reduces myeloid-derived suppressor cells in head and neck cancer.
    Mao L; Deng WW; Yu GT; Bu LL; Liu JF; Ma SR; Wu L; Kulkarni AB; Zhang WF; Sun ZJ
    Int J Cancer; 2017 Mar; 140(5):1173-1185. PubMed ID: 27798955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma.
    Yu GT; Mao L; Wu L; Deng WW; Bu LL; Liu JF; Chen L; Yang LL; Wu H; Zhang WF; Sun ZJ
    Cell Mol Life Sci; 2018 Nov; 75(22):4223-4234. PubMed ID: 29955905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer.
    Wheeler SE; Morariu EM; Bednash JS; Otte CG; Seethala RR; Chiosea SI; Grandis JR
    Clin Cancer Res; 2012 May; 18(10):2850-60. PubMed ID: 22490227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine Kinase Inhibition in HPV-related Squamous Cell Carcinoma Reveals Beneficial Expression of cKIT and Src.
    Kramer B; Kneissle M; Birk R; Rotter N; Aderhold C
    Anticancer Res; 2018 May; 38(5):2723-2731. PubMed ID: 29715092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. γ-Secretase inhibitor reduces immunosuppressive cells and enhances tumour immunity in head and neck squamous cell carcinoma.
    Mao L; Zhao ZL; Yu GT; Wu L; Deng WW; Li YC; Liu JF; Bu LL; Liu B; Kulkarni AB; Zhang WF; Zhang L; Sun ZJ
    Int J Cancer; 2018 Mar; 142(5):999-1009. PubMed ID: 29047105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
    Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
    Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway.
    Yang Z; Liao J; Carter-Cooper BA; Lapidus RG; Cullen KJ; Dan H
    BMC Cancer; 2019 May; 19(1):485. PubMed ID: 31118072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells.
    Zhang Q; Thomas SM; Xi S; Smithgall TE; Siegfried JM; Kamens J; Gooding WE; Grandis JR
    Cancer Res; 2004 Sep; 64(17):6166-73. PubMed ID: 15342401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma.
    Yu GT; Bu LL; Huang CF; Zhang WF; Chen WJ; Gutkind JS; Kulkarni AB; Sun ZJ
    Oncotarget; 2015 Dec; 6(39):42067-80. PubMed ID: 26573233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers.
    Peng S; Creighton CJ; Zhang Y; Sen B; Mazumdar T; Myers JN; Lai SY; Woolfson A; Lorenzi MV; Bell D; Williams MD; Johnson FM
    J Transl Med; 2013 Aug; 11():198. PubMed ID: 23981300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Src family kinases differentially influence glioma growth and motility.
    Lewis-Tuffin LJ; Feathers R; Hari P; Durand N; Li Z; Rodriguez FJ; Bakken K; Carlson B; Schroeder M; Sarkaria JN; Anastasiadis PZ
    Mol Oncol; 2015 Nov; 9(9):1783-98. PubMed ID: 26105207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients.
    Kim YJ; Hong S; Sung M; Park MJ; Jung K; Noh KW; Oh DY; Lee MS; Oh E; Shin YK; Choi YL
    Oncotarget; 2016 Dec; 7(50):82876-82888. PubMed ID: 27756880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
    Johnson FM; Saigal B; Talpaz M; Donato NJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer.
    Liu JF; Ma SR; Mao L; Bu LL; Yu GT; Li YC; Huang CF; Deng WW; Kulkarni AB; Zhang WF; Sun ZJ
    Mol Oncol; 2017 Feb; 11(2):235-247. PubMed ID: 28102051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective blockade of B7-H3 enhances antitumour immune activity by reducing immature myeloid cells in head and neck squamous cell carcinoma.
    Mao L; Fan TF; Wu L; Yu GT; Deng WW; Chen L; Bu LL; Ma SR; Liu B; Bian Y; Kulkarni AB; Zhang WF; Sun ZJ
    J Cell Mol Med; 2017 Sep; 21(9):2199-2210. PubMed ID: 28401653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anterior gradient protein 2 expression in high grade head and neck squamous cell carcinoma correlated with cancer stem cell and epithelial mesenchymal transition.
    Ma SR; Wang WM; Huang CF; Zhang WF; Sun ZJ
    Oncotarget; 2015 Apr; 6(11):8807-21. PubMed ID: 25871396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of adenosine A2A receptor enhances CD8
    Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients.
    Roseweir AK; Qayyum T; Lim Z; Hammond R; MacDonald AI; Fraser S; Oades GM; Aitchison M; Jones RJ; Edwards J
    BMC Cancer; 2016 Mar; 16():229. PubMed ID: 26984511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
    Kim A; Seong KM; Kang HJ; Park S; Lee SS
    Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.